ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31

AbbVie Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$282.68−2.74 (-0.96%)

Close on Oct 19, 2026

Market cap: $500.63B
P/E (TTM): 79.9
Dividend yield: 2.35%

AbbVie Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Stock-Based Compensation	955	911	747	671	692	753	430	421	365	353	282	241	212	187	163
Deferred Income Taxes	-492	-1,449	-2,889	-1,931	-898	-2,325	122	-1,517	-4,162	-796	152	-380	624	104	-332
Other Non-Cash Items	3.00	63	225	150	213	-863	-43	-76	-84	-390	-489	-434	-34	-66	–
Change in Accounts Receivable	-1,490	207	66	-1,455	-1,321	-929	-74	-591	-391	-71	-1,076	-172	681	223	-498
Change in Inventory	-234	-319	-417	-686	-142	-40	-231	-226	93	-38	-434	-203	-56	-203	-87
Change in Accounts Payable	951	177	3,840	1,769	1,719	1,514	97	734	425	-1,187	1,503	-193	-426	-731	1,497
Operating Cash Flow	19,030	18,806	22,839	24,943	22,777	17,588	13,324	13,427	9,960	7,041	7,535	3,549	6,267	6,345	6,247
Capital Expenditures	-1,214	-974	-777	-695	-787	-798	-552	-638	-529	-479	-532	-612	-491	-333	-356
Acquisitions	-204	-17,493	0	-255	-525	-38,260	0	0	0	-2,495	-11,488	-622	-405	-688	-273
Purchase of Investments	-35	-73	-77	-1,438	-119	-61	-583	-1,792	-2,230	-5,315	-851	-1,169	-930	-2,550	-1,943
Sale & Maturity of Investments	76	555	55	1,530	98	1,525	2,699	2,160	2,793	2,359	899	1,477	2,705	1,153	1,255
Other Investing Activities	-29	189	13	774	366	1,387	167	0	0	118	0	0	–	–	–
Investing Cash Flow	-6,643	-20,820	-2,009	-623	-2,344	-37,557	596	-1,006	-274	-6,074	-12,936	-926	879	-2,418	553
Dividends Paid	-11,657	-11,025	-10,539	-10,043	-9,261	-7,716	-6,366	-5,580	-4,107	-3,717	-3,294	-2,661	-2,555	–	–
Share Repurchases	-980	-1,708	-1,972	-1,487	-934	-978	-629	-12,014	-1,410	-6,033	-7,586	-665	-320	–	–
Debt Issued	3,994	16,963	–	2,000	1,000	3,000	31,482	5,963	0	11,627	20,660	–	–	14,586	–
Short-Term Debt Issued (Repaid), Net	499	0	0	–	0	0	-699	299	23	-23	-19	12	-601	1,000	–
Other Financing Activities	68	57	48	30	24	8.00	35	14	21	29	36	-53	-66	-151	-21
Financing Cash Flow	-12,724	-5,211	-17,222	-24,803	-19,039	-11,501	18,708	-14,396	-5,512	-3,928	5,752	-3,293	-3,442	1,931	-6,783
Foreign Exchange Rate Adjustments	42	-65	5.00	-62	-97	-5.00	7.00	-39	29	-338	–	–	–	–	–
Net Change in Cash	-295	-7,290	3,613	-545	1,297	-31,475	32,635	-2,014	4,203	-3,299	51	-1,247	3,694	–	–
Free Cash Flow	17,816	17,832	22,062	24,248	21,990	16,790	12,772	12,789	9,431	6,562	7,003	2,937	5,776	6,012	5,891
Income Taxes Paid	3,626	4,100	4,700	2,988	3,648	1,674	1,447	–	1,696	3,563	1,108	498	1,305	–	–
Interest Paid	3,002	2,811	2,469	2,546	2,712	2,619	1,794	1,215	1,099	986	536	419	283	61	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.5%
Operating margin: 26.2%
Net margin: 9.8%
Return on equity, FY2025: 15367.3%

Financial strength

Current ratio: 0.81
Debt to equity: -11.93
Debt to assets: 52.4%
Cash to current liabilities: 15.8%

Valuation

P/E ratio: 79.9
Price to sales: 7.78
Price to book: –
Dividend yield: 2.35%